Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Michael Friis

Head of Equities

Michael Friis portrait

Coverage

HydractAudientesRealfictionShape RoboticsScape TechnologiesGreenMobilityCurasightOrderYOYOPenneoPhotocatOdicoAgillicBawat Water TechnologiesImperoMapsPeopleNNITNordic SolarScandinavian Medical SolutionsWindowMaster InternationalGomSpaceCABA CapitalAscelia PharmaEmbla MedicalBioPortoGubraExpreS2ion Biotech

Latest content

ShowingAll content types

Curasight (Investment Case): A harsh share price reaction to a good trade-off

Research 10.09.2026 klo 09.15 by Michael Friis, Victor Skriver
Curasight

WindowMaster (Investment case): Record order intake and lower costs set the stage for a strong 2027

Research 09.09.2026 klo 08.30 by Michael Friis, Victor Skriver
WindowMaster International

Gubra (Investment Case): Differentiated way to play obesity, with validation continuing to build

Research 08.09.2026 klo 13.00 by Michael Friis, Victor Skriver
Gubra

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account

ExpreS2ion (Investment Case): Pipeline continues to derisk, near-term question is funding

Research 07.09.2026 klo 09.15 by Michael Friis, Victor Skriver
ExpreS2ion Biotech

BioPorto (Investment Case): Q2 delivered on all parameters set out in the long-term plan

Research 03.09.2026 klo 16.45 by Michael Friis, Victor Skriver
BioPorto

Columbus (Investment Case): AI moving from delivery efficiency into the revenue model

Research 31.08.2026 klo 10.00 by Michael Friis, Victor Skriver
Columbus

Pharma Equity Group (Investment case): Balance sheet de-risked, partnerships remain key

Research 28.08.2026 klo 14.45 by Michael Friis, Victor Skriver
Pharma Equity Group

Curasight: Data read-outs pushed to H1 2027, moving out some near-term catalysts

Analyst Comment 27.08.2026 klo 12.16 by Michael Friis
Curasight

Gubra: Roche's USD 2.3bn UCN2 deal sets a reference point for Gubra's own candidate

Analyst Comment 24.08.2026 klo 12.36 by Michael Friis
Gubra

Agillic (Investment Case): Profitability delivering, growth conversion still pending

Research 24.08.2026 klo 09.00 by Michael Friis, Victor Skriver
Agillic